


A Paradigm Shift in Minimally Invasive Surgery



About Us

An exclusive provider of innovative, minimally invasive medical laser systems and consumables for multiple medical disciplines, principally in the field of urology. Solutions also include clinical education, service, support and maintenance.

Focus on:

- increasing the availability of services for patients
- enhancing the quality of patient care
- improving operational efficiencies and outcomes
- reducing total operational costs

Our lasers target these issues:

Benign Prostate Hyperplasia (BPH), urinary stones (bladder & kidney) and female incontinence.

CAPITAL STRUCTURE

(As of September 2019)

Share Price	\$0.40
52 Week High/Low	\$0.51/\$0.20
Market Cap	~\$8.4 M
Shares Outstanding	~21 M
Warrants & Options	3.6 M
Fully Diluted	24.7 M

Highlights

- ASTI's state-of-the-art proprietary FDA approved holmium laser fiber for kidney and bladder stones is gaining momentum in the market as a true innovation in laser lithotripsy.
 - Production began in the first quarter of 2019. Future consumable sales will grow as this will be the only fiber optic which will be locked and matched to the high power HYPHO Holmium laser.
- ASTI's flagship laser for Benign Prostate Hyperplasia continues to grow market share with multiple product evaluations scheduled at private practices, surgical centers and university teaching hospitals across the country.
- Multiple ongoing negotiations with leading manufacturers and distributors of surgical instruments to the urology/gynaecology marketplace are taking place in the US.

Management Team & Board

Gordon Willox

President & Chief Technical Officer

David Hennigar

Chairman

Gary Van Nest

Director, CEO & Vice Chairman

Dr. Robert W. Francis MD

Founder, Director & Chief Medical Officer of MedCan Clinic, ASTI Director


Dr. Stan Swierzewski III MD

Chief of Urology & ASTI Director



The US Market Opportunity is Enormous

Laser BPH Market



Normal Prostate


Enlarged Prostate

43

Million Men

\$21.3B

Laser Urinary Stone Market



30

Million People

\$5.5B

Laser Incontinence Market



31

Million Women

\$16.3B

TOTAL ESTIMATED US MARKET: \$40B+

“Last year, we had spent most of our time on educational and training sessions across the US. Now that our technology has been successfully tested by numerous well-regarded surgeons and institutions, we are focused on ramping up sales and are already securing new sales distribution agreements.”

– Gordon Willox, President

For more information, please contact:

Gordon Willox, President

E: gordonwillox@live.ca

T: +1-844-441-9090

Cathy Hume, Investor Relations

E: cathy@chfir.com

T: 416.868.1079 x 231